Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status Prescription
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 66689-108; 52038-005; 36998-1810; 27808-245; 50228-195; 69539-026; 36998-2477; 67877-733; 68462-678; 14445-012; 65977-0075; 14445-130; 50370-0024; 36998-2478; 68462-681; 65162-925; 47335-922; 69539-025; 0131-5410; 51991-349; 51991-350; 65162-924; 0131-1810; 62331-062; 69539-027; 51991-351; 36998-0119; 36998-2480; 65862-720; 66689-107; 50228-194; 27808-246; 31722-815; 0131-2479; 62332-172; 51991-348; 46708-860; 50228-192; 31722-814; 53296-0101; 0904-7247; 14445-129; 0904-7245; 68462-679; 66689-109; 50228-193; 36998-2479; 17205-107; 25021-791; 13612-0021; 65162-926; 62332-173; 0131-2477; 31722-812; 62332-171; 66651-914; 70166-617; 16436-0101; 67877-735; 14445-406; 14445-132; 66039-882; 67877-736; 0904-7246; 14445-021; 69539-028; 17180-2746; 27808-243; 62332-174; 67877-734; 31722-813; 47335-980; 65372-1186; 0131-2480; 47335-943; 66689-110; 0904-7244; 68225-057; 14445-131; 68462-680; 53747-069; 47335-918; 0131-2478; 27808-244; 12828-0087; 65162-923
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Confusional state19.13.01.001; 17.02.03.0050.056982%
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.006704%Not Available
Cough22.02.03.001--
Crying08.01.03.005; 19.04.02.002; 17.02.05.013; 12.02.11.0010.006704%Not Available
Deafness04.02.01.0010.006704%Not Available
Death08.04.01.0010.076948%
Delirium19.13.02.0010.030167%
Delusion19.10.01.0010.006704%
Depressed level of consciousness17.02.04.0020.016759%
Depressed mood19.15.02.001--Not Available
Depression19.15.01.0010.070390%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.0050.043575%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.023463%Not Available
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.140779%
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.013408%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug withdrawal convulsions17.12.03.016; 08.06.02.0030.006704%Not Available
Dry mouth07.06.01.002--
Dysarthria19.19.03.001; 17.02.08.0010.020111%
Dyskinesia17.01.02.0060.016759%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dystonia17.01.03.0010.006704%Not Available
Ear disorder04.03.01.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages